Biotechnology

Filter

Current filters:

None

Popular Filters

2026 to 2050 of 2250 results

Xenon in $646 million deal with Roche unit

10-01-2012

Canada based Xenon Pharmaceuticals, a privately-owned, clinical genetics-based drug discovery and development…

BiotechnologyGenentechLicensingNeurologicalPharmaceuticalResearchRocheXenon Pharmaceuticals

LEO Pharma in over $300 million deal for psoriasis therapy

10-01-2012

Privately-held Danish drugmaker LEO Pharma A/S has signed a multi-million dollar in-licensing deal with…

BiotechnologyDermatologicalsLEO PharmaLicensingPharmaceuticalVirobay

Dendreon upbeat on Provenge sales

08-01-2012

US biotech firm Dendreon (Nasdaq: DNDN) pleased investors last week when it reported that revenue of…

BiotechnologyDendreonFinancialMarkets & MarketingOncologyProvenge

Drugmakers taking steps to improve R&D productivity, says Tufts CSDD

08-01-2012

Even though pharmaceutical companies are pursuing innovative approaches to increase the pace and reduce…

BiotechnologyPharmaceuticalResearch

Bionomics in $345 million CNS deal with Ironwood

06-01-2012

Australian biotech firm Bionomics (ASX: BNO) entered into a collaboration, research and licensing agreement…

BionomicsBiotechnologyIronwood PharmaceuticalsLicensingNeurologicalPharmaceuticalResearch

Smith & Nephew to spin-out biologics and clinical therapies unit

05-01-2012

Texas, USA-based venture capital firm Essex Woodlands has entered into a strategic partnership with the…

BiotechnologyBioventusMergers & AcquisitionsSmith & Nephew

Isis Pharma could earn $299 million from Biogen Idec deal

05-01-2012

US biotech firm Biogen Idec (Nasdaq: BIIB) has entered into an exclusive, worldwide option and collaboration…

Biogen IdecBiotechnologyIsis PharmaceuticalsLicensingRare diseasesResearch

Many NIH-funded clinical trials go unpublished

04-01-2012

In a study that investigates the challenges of disseminating clinical research findings in peer-reviewed…

BiotechnologyPharmaceuticalResearch

Phylogica signs deal with Johnson & Johnson unit

04-01-2012

Australian peptide drug discovery company Phylogica (ASX: PYC) has entered into a collaboration and option…

BiotechnologyFinancialJanssen BiotechJohnson & JohnsonLicensingPharmaceuticalPhylogica

Biotech predictions for 2012 from sector specialist Steven Burrill

03-01-2012

As 2011 drew to a close, Steven Burrill, chief executive of global life sciences financial services firm…

BiotechnologyFinancialMergers & AcquisitionsNorth AmericaPharmaceuticalRegulation

Baxter taps Momenta expertise on biosimilars

28-12-2011

In another move to capitalize on the anticipated flood of biosimilars coming to the market, as blockbuster…

Baxter InternationalBiotechnologyGenericsLicensingMomenta PharmaceuticalsResearch

Exelixis and Sanofi terminate $1 billion cancer deal

23-12-2011

US biotechnology firm Exelixis (Nasdaq: EXEL) says its oncology deal with French drug Major Sanofi (Euronext:…

BiotechnologyExelixisLicensingOncologyPharmaceuticalResearchSanofi

New EMA measures to facilitate conduct of ENCePP studies

22-12-2011

The European Medicines Agency and the European Network of Centers for Pharmacoepidemiology and Pharmacovigilance…

BiotechnologyEuropePharmaceuticalRegulationResearch

EU patent a step nearer

20-12-2011

The European Union came a step closer to getting a single patent system on Tuesday, when a deal struck…

BiotechnologyEuropePatentsPharmaceutical

Amgen in cancer biosimilars deal with Watson

20-12-2011

A collaboration has been entered into by Amgen (Nasdaq: AMGN), the world’s largest independent biotech…

AmgenBiotechnologyGenericsGlobalLicensingMarkets & MarketingOncologyWatson Pharmaceuticals

Plant molecular farming: a new Biotech Wave

19-12-2011

Currently, the two approved methods of biopharmaceuticals manufacturing widely used in Europe are mammalian…

BASFBayerBiotechnologyPharmaceuticalResearch

Gilead filing of Truvada for PrEP looks contentious

19-12-2011

US biotech firm Gilead Sciences’ (Nasdaq: GILD) decision last week to submit a supplemental New…

Anti-viralsBiotechnologyGilead SciencesNorth AmericaPharmaceuticalRegulationTruvada

Musical chairs at Amgen and Roche

19-12-2011

USA-based Amgen (Nasdaq: AMGN), the world’s largest independent biotech company, says that Kevin…

AmgenBiotechnologyManagementPharmaceuticalRoche

Germany’s IQWIG negative on InterMune’s Esbriet

18-12-2011

US biotech firm InterMune (Nasdaq: ITMN) says that Germany’s private Institute for Quality and Efficiency…

BiotechnologyEsbrietEuropeInterMuneRare diseasesRegulationRespiratory and Pulmonary

2026 to 2050 of 2250 results

Back to top